Retatrutide has emerged as a new pharmaceutical in the fight against obesity. This novel drug, categorized as a dual GLP-1 and GIP receptor agonist, exhibits promising results in clinical trials. By stimulating these https://aronkvwv639156.sharebyblog.com/35947340/tirzepatide-a-promising-new-treatment-for-obesity